August 4, 2025 7:53am

An exclamation and an imperative verb that means gradually increase numbers however a weak and quasi mixed aftermarket with no big “flash” econs this week coming

Earnings season rolls on: Cellectis SA (CLLS) and BioNTECH (BNTX)

Pre-open Signals: 5 Positive Indications

Never leave an investor uninformed … I try to rationalize the whys of inclines or declines in share pricing as lately it seems no news is good news

I say what others won’t, so you can do what others can’t!

Stocks tumbled on Friday to kick off August trading as investors weighed stark signs of a weakening economy … breadth had been <hoping to improve> narrowing, valuations are stretched thinly, and an offensive <buying>  positioning is quietly building ... even as cell and gene therapy earnings season rolls on

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

 

Friday’s night’s … RegMed Investors (RMi) Closing Bell: Feet wet … Deploy the proper rescue i.e., as the Fed has been given multiple econs’ lack of strength! … https://www.regmedinvestors.com/articles/14045

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB): Sustaining a Loser … https://www.regmedinvestors.com/articles/13812

 

Monday: The pre-open Dow futures are UP +0.52% or (+227 points), the S&P futures are UP +0.62% or (+38 points) and the Nasdaq futures are UP +82% or (+187 point)

  • Stock futures climbed Monday as traders tried to claw back the steep losses seen in the previous session,
  • European markets were positive, Monday 8/4,
  • Asia-Pacific markets mostly rose.

 

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

  • Friday: The Dow closed DOWN -542.40 points or -1.23%, the S&P closed DOWN -101.38 points or -1.60% while the Nasdaq closed DOWN -472.32 points or -2.24%
  • Thursday: The Dow closed DOWN -330.30 points or -0.74%, the S&P closed DOWN -25.35 points or -0.37% while the Nasdaq closed DOWN -7.23 points or -0.03%
  • Wednesday: The Dow closed DOWN -171.71 points or -0.38%, the S&P closed DOWN -7.96 points or -0.12% while the Nasdaq closed UP +31.38 points or +0.15%
  • Tuesday: The Dow closed DOWN -204.57 points or -0.46%, the S&P closed DOWN -18.91 points or -0.30% while the Nasdaq closed DOWN -80.29 points or -0.38%
  • Monday: The Dow closed DOWN -64.36 points or -0.14%, the S&P closed UP +1.13 points or +0.02% while the Nasdaq closed UP +70.27 points or +0.33%
  • The past week, with and the Dow tumbled -2.9% <its worst week since April 4>, the S&P 500 dropped -2.4% <for its worst weekly performance since May 23> and the Nasdaq lost -2.2%.

Economic Data Docket: factory orders

 

Q3 – August - 1 negative close

  • July – 1 market holiday, 13 positive and 9 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

  • I’ll pass; ….  maybe less econs, more earnings, ups, downs and just plain uncertainty

Although:

Alnylam Pharmaceuticals (ALNY +$9.56 after Thursday’s +$52.44, Wednesday’s +$9.25, Tuesday’s +$5.76 and Monday’s -$4.02 with a positive +$0.60 or +0.20% pre-open

Vericel (VCEL +$0.69 after Thursday’s -$5.72 after Wednesday’s +$0.80, Tuesday’s -$1.59 and Monday’s +$1.33 with a positive +$0.37 or +1.04% pre-open

Beam Therapeutics (BEAM) closed down -$0.88 after Thursday’s -$0.44 after Wednesday’s +$0.22, Tuesday’s -$0.90 and Monday’s -$0.89 with a positive +$0.11 or +0.58% pre-open

Moderna (MRNA) closed down -$1.95 with earnings release after Thursday’s -$2.59 with a positive +$0.49 or +12.76% pre-open

CRISPR Therapeutics (CRSP) closed down -$0.17 after Thursday’s -$1.42, Wednesday’s -$1.34, Tuesday’s -$4.73 and Monday’s -$1.01 with a positive +$0.99 or +1.77% pre-open 

 

The BOTTOM LINE:  Are we looking at the cell and gene therapy sector … STABILIZING today … more than a hope even within earnings season …

Futures rose on Monday, stabilizing after a turbulent session as investors priced in deeper interest rate cuts by the Fed following a soft jobs report last week.

  • Indexes tumbled on Friday, with the S&P 500 recording its largest daily % decline in over 2 months, as new U.S. tariffs on dozens of trading partners and a much weaker-than-expected July jobs report spurred selling pressure.
  • Sentiment also took a turn for the worse last week after an executive order signed by Trump imposed fresh import duties on trading partners, in
  • U.S. factory orders data for June is due at 10:00 a.m. ET. Tuesday's business activity report and Thursday's jobless claims figures are the only other key economic indicators in this data-light week.  <Reuters and H>

 

August begins as July ends: understand the “flow” …

  • 8/1 – Friday closed negative with 9 positive, 20 negative and 6 flats
  • 7/31 - Thursday closed negative with 3 positive, 25 negative and 7 flats
  • 7/30 - Wednesday closed negative with 12 positive, 18 negative and 5 flats
  • 7/29 – Tuesday closed negative with 8 positive, 22 negative and 5 flats
  • 7/28 – Monday closed negative with 14 positive, 16 negative and 5 flats

 

Earnings; 8/5, Tuesday = Supernus Pharma (SUPN) <aquired SAGE>, AxoGen (AXGN) and Ultragenyx Pharmaceuticals (RARE) and 8/11, Monday = Agenus (AGEN)

  • Meeting earnings expectation and/or missing consensus will deem share pricing outcomes this week.

Earnings to date:

  • Moderna (MRNA) a net loss of -$0.8 B, or -$2.13 per share with revenue of $142 M, an R&D and an SG&A decrease and a cash position of $7.5 B with a runway until 2026 <beats revenue estimate and earnings consensus>.
  • Sage Therapeutics (SAGE): net loss of -$49.7 M or -$0.79 per share, revenue of $23.2M, a cash position of $366 M – acquired
  • Vericel (VCEL): net loss of -$0.06 M or -$0.01 per share, revenue of $63.2M, a cash position of $164 M and a runway until 2027
  • Alnylam Pharmaceuticals (ALNY): net loss of -$66.3 M or -$0.51 per share, revenue of $773.7 M, a cash position of $2.86 B and a N/A runway
  • Lenz Therapeutics (LENZ): net loss of -$14.9 M or -$0.53 per share, revenue of $5 M, a cash position of $209.6 M and a runway until 2026
  • uniQure NV (QURE): a net loss of -$37.7 M, or -$0.69 per share with revenue of $5.3 M, an R&D increase and an SG&A decrease and a cash position of $377.7 M with a runway until 2H/27 <missed revenue estimate and consensus>
  • Ionis Pharmaceuticals (IONS): a net income of +124 M, or +$0.70 per share with revenue of $452 M, and a cash position of $2.3 B with a runway until FY28 < estimate and consensus beats>
  • MiMedx (MDXG): a net income of +$100 M or +$0.06 per share with revenue of $99 M and a cash position of $100 M with a runway until 2026.

 

“I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

 

Reiterating, “There are always some big ifs, especially given some of the headlines that could emanate after a past few months of news flatulence.

  • As always, I brace myself for earnings associated with share pricing volatility, some economics and tariff developments and their effects?

Welcome to my world of defining the “grey’ in our universe!

  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

 I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.